Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Jefferies Downgrades SAP to Underperform

Jefferies analyst Charles Brennan downgrades SAP (NYSE:SAP) from Buy to Underperform.
byBenzinga Newsdesk
November 18, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Jefferies analyst Charles Brennan downgrades SAP (NYSE:SAP) from Buy to Underperform.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept’s ‘OCA In NASH May Never Occur

By Vandana Singh
May 22, 4:20 PM
On Friday, FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's ICPT Ocaliva 25 mg, also known as Obeticholic acid (OCA), don't outweigh the risks in nonalcoholic steatohepatitis (NASH) 

CBAY